These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9924431)

  • 1. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
    Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
    J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
    Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
    Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
    Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
    J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
    Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
    Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer.
    Omran OM; Ata HS
    Ultrastruct Pathol; 2012 May; 36(3):145-52. PubMed ID: 22559040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells.
    Kuncová J; Urban M; Mandys V
    APMIS; 2007 Nov; 115(11):1194-205. PubMed ID: 18092951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas.
    Daniel L; Lechevallier E; Giorgi R; Lindner V; De Fromont M; Vieillefond A; Coulange C; Figarella-Branger D
    J Pathol; 2001 Mar; 193(3):345-9. PubMed ID: 11241414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cathepsin D in transitional cell bladder tumours.
    Lipponen PK
    J Pathol; 1996 Jan; 178(1):59-64. PubMed ID: 8778318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study.
    Morris SF; O'Hanlon DM; McLaughlin R; McHale T; Connolly GE; Given HF
    Eur J Surg Oncol; 2001 Sep; 27(6):527-31. PubMed ID: 11520083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression.
    Saegusa M; Machida D; Hashimura M; Okayasu I
    J Pathol; 1999 Nov; 189(3):326-37. PubMed ID: 10547593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma.
    Chai CY; Chen WT; Hung WC; Kang WY; Huang YC; Su YC; Yang CH
    J Clin Pathol; 2008 May; 61(5):658-64. PubMed ID: 17908805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer.
    Müller W; Schneiders A; Heider KH; Meier S; Hommel G; Gabbert HE
    J Pathol; 1997 Oct; 183(2):222-7. PubMed ID: 9390037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
    Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
    Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage?
    Regauer S; Ott A; Berghold A; Beham A
    J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.
    Ristamäki R; Joensuu H; Söderström KO; Jalkanen S
    J Pathol; 1995 Jul; 176(3):259-67. PubMed ID: 7545748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis.
    Lipponen PK; Aaltomaa S
    J Pathol; 1994 Aug; 173(4):333-9. PubMed ID: 7965393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
    Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
    Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer.
    Lipponen PK; Eskelinen MJ; Kiviranta J; Nordling S
    Anticancer Res; 1991; 11(2):911-6. PubMed ID: 2064350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53 protein has no independent prognostic value in breast cancer.
    Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
    J Pathol; 1995 Nov; 177(3):225-32. PubMed ID: 8551383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.